Literature DB >> 15321399

General anaesthesia using remifentanil for caesarean section in parturients with critical aortic stenosis: a series of four cases.

R M L E Orme1, C S Grange, Q P Ainsworth, C R Grebenik.   

Abstract

Although heart disease is now the joint leading cause of maternal mortality in the UK, critical aortic stenosis is rarely encountered in parturients. Caesarean section is advisable in these patients to minimise the haemodynamic stress of labour and delivery. The use of an opioid-based general anaesthetic technique also helps to maintain cardiovascular stability. During a two-year period, four women with critical aortic stenosis requiring caesarean section presented to our institution. In all women, a rapid sequence induction of anaesthesia was performed using etomidate 0.1 to 0.2 mg.kg(-1), suxamethonium 1.5 mg.kg(-1) and remifentanil 2 to 4 micrograms.kg(-1). Anaesthesia was then maintained with isoflurane, nitrous oxide and a remifentanil infusion at 0.05 to 0.15 micrograms.kg(-1)min(-1). There was good haemodynamic stability throughout, except for a short period in one patient who became hypotensive after a significant post-partum haemorrhage secondary to uterine atony. All parturients were successfully extubated at the end of surgery and made excellent postoperative recoveries. Neonates were born in good condition with Apgar scores of 10, 9, 6 and 5 at 1 min and 10, 10, 10 and 10 at 5 min. We suggest that remifentanil is an ideal agent for parturients with severe aortic stenosis requiring general anaesthesia for caesarean section. Remifentanil provides cardiovascular stability in conjunction with rapid emergence from anaesthesia in the parturient and minimal side effects in the neonate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15321399     DOI: 10.1016/j.ijoa.2003.12.008

Source DB:  PubMed          Journal:  Int J Obstet Anesth        ISSN: 0959-289X            Impact factor:   2.603


  9 in total

1.  Remifentanil use for cesarean section in a patient with intracranial re-ruptured arteriovenous malformation.

Authors:  Eiko Onishi; Akiko Kojima; Toshio Saishu; Shin Kurosawa
Journal:  J Anesth       Date:  2011-12-11       Impact factor: 2.078

Review 2.  Induction of anaesthesia: a guide to drug choice.

Authors:  Nathalie Nathan; Isabelle Odin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Mitral stenosis and pregnancy: Current concepts in anaesthetic practice.

Authors:  M Kannan; G Vijayanand
Journal:  Indian J Anaesth       Date:  2010-09

Review 4.  Anesthesia for pregnant women with valvular heart disease: the state-of-the-art.

Authors:  Krzysztof M Kuczkowski; André van Zundert
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

5.  Anesthetic management for cesarean delivery in a patient with severe aortic stenosis and severe obesity.

Authors:  Subhamay Ghosh; Sandor Marton
Journal:  Obes Surg       Date:  2009-08-29       Impact factor: 4.129

6.  Neonatal effect of remifentanil in general anaesthesia for caesarean section: a randomized trial.

Authors:  Pavlina Noskova; Jan Blaha; Hana Bakhouche; Jana Kubatova; Jitka Ulrichova; Patricia Marusicova; Jan Smisek; Antonin Parizek; Ondrej Slanar; Pavel Michalek
Journal:  BMC Anesthesiol       Date:  2015-03-26       Impact factor: 2.217

7.  Efficacy and safety of remifentanil for analgesia in cesarean delivery.

Authors:  Xuan Zhou; Lian-Jin Jin; Chun-Yang Hu; Meng Chen; Ying Li; Yue-Shun Zhang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Anaesthetic management of parturient with acute atrial fibrillation for emergency caesarean section.

Authors:  Madhu Gupta; Shalini Subramanian; Preeti Adlakha
Journal:  Case Rep Anesthesiol       Date:  2013-05-27

9.  Remifentanil at induction of general anesthesia for cesarean section: Double blind,randomized clinical trial.

Authors:  Shekoufeh Behdad; Vida Ayatollahi; Hamid Harrazi; Naderali Nazemian; Najmeh Heiranizadeh; Behnam Baghianimoghadam
Journal:  Colomb Med (Cali)       Date:  2013-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.